IFRX Stock Catalyst: InflaRx Announces Development of Izicopan for AAV Treatment

May 5, 2026 · 7:36pm ET

Company to focus on oral C5A receptor inhibitor for kidney disorder.

Max move

+46.6%

High of day $2.86

Sparker timei

7:36pm ET

IFRX · May 5, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

InflaRx N.V. (Nasdaq: IFRX) has announced its intention to develop Izicopan, an oral C5A receptor inhibitor, for the treatment of ANCA-associated vasculitis (AAV), a life-threatening kidney disorder. The company aims to leverage its expertise in complement system inhibition to address this unmet medical need.

The development of Izicopan is part of InflaRx's broader strategy to expand its pipeline of complement-inhibiting therapies. The company has a free float of 60,014,640 shares and 72,292,859 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time IFRX sparks.

Download Sniper App →

Catch the next IFRX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →